Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ™ technology
08 janv. 2025 08h00 HE
|
Araris Biotech
Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive an upfront fee and milestone payments...
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
07 janv. 2025 04h30 HE
|
Pentixapharm Holding AG
BERLIN, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pentixapharm AG, a developer of innovative radiopharmaceuticals, receives 6.77 million Euro for intangible assets formerly developed by Glycotope from...
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
10 déc. 2024 07h00 HE
|
Relation Therapeutics
FOR IMMEDIATE RELEASERelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry...
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
10 déc. 2024 02h00 HE
|
Relation Therapeutics
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying...
OMERS Private Equity announces agreement to acquire Integris, a leading provider of IT services in the United States
03 déc. 2024 09h15 HE
|
OMERS
OMERS Private Equity today announced the signing of a definitive agreement to acquire a majority stake in Integris.
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
15 nov. 2024 04h30 HE
|
Numab Therapeutics AG; Kaken Pharmaceutical Co., Ltd.
Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...
ME INVESTOR UPDATE: Shareholders of 23andMe Holding Co. are Alerted of Pending Investigation into the Company; Contact BFA Law if You Own Substantial Shares (Nasdaq:ME)
29 sept. 2024 06h40 HE
|
Bleichmar Fonti & Auld
23andMe Holding Co. shareholders are encouraged to contact BFA Law about its investigation into the Board for breaches of fiduciary duties.
Evaxion significantly expands vaccine development collaboration with MSD
26 sept. 2024 07h30 HE
|
Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
Johnson Fistel, LLP Investigates Envestnet Deal Terms and for Potential Violations of Fiduciary Duties on Behalf of Shareholders
28 août 2024 13h25 HE
|
Johnson Fistel, LLP
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading stockholder rights law firm, announced today that it has initiated an investigation into the board members of Envestnet,...
Is Envestnet's $63.15 Per Share Sale Price Fair? Johnson Fistel, LLP Investigates Deal Terms
13 août 2024 10h25 HE
|
Johnson Fistel, LLP
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading stockholder rights law firm, announced today that it has initiated an investigation into the board members of Envestnet,...